Results pending
Lipid / vascular (statins etc.): reduce relapses and new lesions in relapsing MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
relapsing MS · Lipid / vascular (statins etc.)
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 8
- Running now
- 0
- Controlled phase 2/3 trials
- 3
- People in controlled trials
- 270
How the verdict was reached
Phase 2 results not all read yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| ARIANNA | Phase 2 | 150 | 2006 | No results found Paper abstract | Will count once its result is read |
| Pravastatin, phase 3 | Phase 3 | 40 | 2004 | No results found Paper abstract | Will count once its result is read |
| irmsrct | Phase 3 | 80 | 2005 | Met its main goal The total attack number in the simvastatin group was significantly lower than placebo group (moderate effect size r = 0.29) (p = 0.01). Paper abstract | Counted |
| Simvastatin, phase 3 | Phase 3 | 30 | 2005 | No results found Paper abstract | Not counted: not randomised |
| Simvastatin/Copaxone | Phase 3 | 0 | 2008 | Stopped | Not counted: added on top of a medicine that already controls relapses, so a miss says little |
| SIMCOMBIN | Phase 4 | 380 | 2006 | Paper found, not read | Not counted: phase 1 or phase 4 |
| Interferon beta, phase 2 | Phase 2 | 41 | 2003 | Paper found, not read | Not counted: not randomised |
| SWABIMS | Phase 2 | 77 | 2005 | Missed its main goal At study end, the proportion of patients with new lesions on T2-weighted images was equal in both groups (odds ratio 1.14; 95 % CI 0.36-3.56; p = 0.81). Paper abstract | Not counted: not randomised |
Counted: 1. Will count later: 2. Not counted: 5.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Results pending